ArticleFrontiers in oncology2025
Clinical features and prognostic analysis of spontaneous rupture of renal cell carcinoma: a retrospective cohort study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spontaneous Rupture of a Small Chromophobe Renal Cell Carcinoma Presenting as Wunderlich Syndrome.IJU case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spontaneous rupture of renal cell carcinoma (SRRCC) is a rare but critical clinical manifestation characterized by the acute disruption of tumor integrity, leading to extravasation of tumor contents into the perirenal space and associated complications. Understanding its clinical features, risk factors, and prognosis is essential for optimizing diagnosis and treatment. Methods: This retrospective, single-center study analyzed 37 cases of SRRCC from 165 patients with spontaneous renal tumor rupture treated between April 2014 and June 2024. Clinical, pathological, and laboratory data were collected and analyzed. Kaplan-Meier survival analysis and univariate Cox regression were used to evaluate cancer-specific survival (CSS) and progression-free survival (PFS). Results: The median age of SRRCC patients was 49 years (IQR: 38-60), with males accounting for 59.5%. Tumors were predominantly located in the left kidney (70.3%), with clear cell renal cell carcinoma (ccRCC) being the most common histological subtype (56.8%). The median tumor size was 6.5 cm(IQR: 4.1-10.1). The most frequent symptom was flank or abdominal pain (83.8%). Preoperative laboratory tests showed elevated APTT, PT, D-dimer, and fibrinogen levels. Radical nephrectomy was performed in 64.9% of patients, and 48.6% underwent emergency surgery. The median follow-up duration was 60 months (IQR: 27-80). The median cancer-specific survival (CSS) and progression-free survival (PFS) were 60 months (IQR: 27-80) and 49 months (IQR: 19-80), respectively. The 5-year CSS and PFS rates were 80.1% (95% CI: 64.0%-96.2%) and 68.8% (95% CI: 51.4%-86.2%), respectively, as estimated by the Kaplan-Meier method. Prognostic factors significantly associated with CSS and PFS included TNM stage, WHO/ISUP grade, tumor size, perirenal fat invasion, and coagulation abnormalities. Conclusions: SRRCC presents unique diagnostic and therapeutic challenges due to its acute nature and potential for tumor dissemination. Prognosis was associated with tumor characteristics and coagulation markers, while surgical timing and type was not significantly associated with outcomes. Further multicenter studies with larger cohorts are needed to validate these findings and guide clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.